Jon Chatzkel, MD
Jon Chatzkel, MD
Program: Genitourinary Oncology
-
Overview
Dr. Chatzkel is a clinical investigator with a research focus on novel therapeutic strategies for genitourinary cancers. His work explores novel combinations involving immune checkpoint inhibitors as well as antibody-drug conjugates and other targeted therapies. He is interested in the use of biomarkers to guide therapy -- particularly the use of circulating tumor DNA to evaluate for the presence of minimal residual disease and to personalize anti-cancer therapy.
Associations
- Genitourinary Oncology
-
Research Interest
- Evaluation of novel combinations involving immunotherapy. For example, I have served as a site PI in trials combining the VEGFR-TKI zanzalintinib and nivolumab (in patients with kidney cancer) and enfortumab vedotin and pembrolizumab (in patients with urothelial cancer). I also was co-principal investigator in a study of atezolizumab plus tivozanib in immunologically cold tumors. - Evaluation of the use of anti-body drug conjugates, particularly in bladder cancer, and particularly following the development of resistance to enfortumab vedotin. - Bladder sparing approaches in patients with muscle invasive bladder cancer. - The use of biomarkers such as circulating tumor DNA to guide adjuvant therapy in bladder and/or kidney cancer. - Novel radioligand therapies. - The implementation of novel educational interventions for hematology/oncology fellows, such as a faculty-developed spaced repetition program.
-
Publications
- Chatzkel J, Linscott J, Daniel Grass G, Li R. Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies. Eur Urol Focus. 2025 Jul. Pubmedid: 40716995.
- Chatzkel J, Schell MJ, Chahoud J, Zhang J, Jain R, Swank J, Ludlow S, Lombardi K, Lucas Y, Croft C, Rembisz J, Jameel G, Fishman M. Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. Clin Genitourin Cancer. 2022 Jun.20(3):252-259. Pubmedid: 35249821.
- Chatzkel J, Mocha J, Smith J, Zhou JM, Kim Y, El-Haddad G, Zhang J. Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients. Future Sci OA. 2019 Dec.6(1):FSO437. Pubmedid: 31915536. Pmcid: PMC6920735.